NM Care ACO

ACO Name and Location:

NM Care ACO, LLC
123 East Marcy Street, Suite 101
Santa Fe, NM 87501

ACO Primary Contact:

Michael Wallace
Michael.Wallace2@davita.com
505-262-3907

Organizational Information:

  • ACO Participants:
 1. DaVita Medical Group New Mexico, LLC
 2. Aspen Medical Group, LLC
 3. Elizabeth A. Morgan, MD, LLC
 4. Hospice of New Mexico, LLC
 5. Margaret J. Nolan, M.D. PC
 6. Patricia Conkling, CNP, LLC
 7. Rio Abajo Family Practice, PC
  • ACO participants in joint ventures between ACO professionals and hospitals (annotated by asterisk [*])

  • ACO Governing Body:
 Brendan Dowing, MHA, Voting Member and Executive Chair, ACO Participant, DaVita Medical Group New Mexico
 Dr. Lance Wilson, Medical Director, Voting Member, ACO Participant, DaVita Medical Group New Mexico
 Dr. Nishiena Gandhi, Voting Member, ACO Participant, DaVita Medical Group New Mexico
 Dr. Barbara McAneny, Voting Member, ACO Affiliate, New Mexico Oncology Hematology Consultants
 Joan Uhlmansiek, Voting Member, Medicare Beneficiary Representative
 Dr. Andrew Mason, Voting Member, ACO Affiliate, Southwest Gastroenterology Associates
 Traci Bolton, Voting Member, ACO Participant, DaVita Medical Group New Mexico
 Bindu Purushothaman, Voting Member, ACO Participant, DaVita Medical Group New Mexico
 Dr. Norah Walsh, Voting Member, ACO Participant, Rio Abajo Family Practice 
 Dr. Margaret Nolan, Voting Member, ACO Participant, Hospice of New Mexico 
 Dr. Andrew Ropp, Voting Member, ACO Participant, Aspen Medical Group
 Joon Lee, Voting Member, ACO Participant, DaVita Medical Group New Mexico 
 Dr. Robert White, Non-Voting Member, Other, DaVita Medical Group New Mexico 
 Mallory Markham, Non-Voting Member, Other, DaVita Medical Group New Mexico 
 Michael Wallace, Non-Voting Member, Other, DaVita Medical Group New Mexico
 
  • Key ACO Clinical and Administrative Leadership:
ACO Executive: Brendan Dowling, MHA
Medical Director, Quality Assurance/Improvement Officer: Dr. Lance Wilson
Compliance Officer: Mallory Markham
 
  • Associated Committees and Committee Leadership:
Patient Experience and Engagement: Joan Uhlmansiek, Chair
Governance: Michael Wallace, Chair
Population Health: Dr. Lance Wilson, Chair
Finance: Traci Bolton, Chair
IT: Bindu Purushothaman, Chair
Compliance Committee: Mallory Markham, Chair
Nominating: Joon Lee, Chair
 
Types of ACO participants, or combinations of participants, that formed the ACO:

        ACO professionals in a group practice arrangement

        Networks of individual practices of ACO professionals

 

Shared Savings and Losses: N/A

Shared Savings Distribution: N/A 

Payment Rule Waivers:

No, our ACO does not use the SNF 3-Day Rule Waiver.

 

Quality Performance Results:

2017 Quality Performance Results

ACO#

Measure Name

NM Care ACO Rate

SSP ACO Mean

ACO-1

CAHPS: Getting Timely Care, Appointments, and Information

69.35  

80.60

ACO-2

CAHPS: How Well Your Providers Communicate

90.57

93.13

ACO-3

CAHPS: Patients' Rating of Provider

89.95

92.31

ACO-4

CAHPS: Access to Specialists

77.67

83.32

ACO-5

CAHPS: Health Promotion and Education

58.50

62.30

ACO-6

CAHPS: Shared Decision Making

77.94

75.85

ACO-7

CAHPS: Health Status/Functional Status

71.40

73.05

ACO-34

CAHPS: Stewardship of Patient Resources

17.13

25.68

ACO-8

Risk-Standardized, All Condition Readmission

14.78

15.01

ACO-35

Skilled Nursing Facility 30-Day All-Cause Readmission Measure (SNFRM)

17.19

18.46

ACO-36

All-Cause Unplanned Admissions for Patients with Diabetes

40.69

53.95

ACO-37

All-Cause Unplanned Admissions for Patients with Heart Failure

63.78

79.16

ACO-38

All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions

43.68

61.74

ACO-9

Ambulatory Sensitive Conditions Admissions: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults (AHRQ Prevention Quality Indicator (PQI) #5)

N/A

9.27

ACO-10

Ambulatory Sensitive Conditions Admissions: Heart Failure (AHRQ Prevention Quality Indicator (PQI) #8 )

N/A

14.53

ACO-11

Percent of PCPs who Successfully Meet Meaningful Use Requirements

100

91.17

ACO-39

Documentation of Current Medications in the Medical Record

N/A

87.54

ACO-13

Falls: Screening for Future Fall Risk

21.50

74.38

ACO-14

Preventive Care and Screening: Influenza Immunization

72.40

72.52

ACO-15

Pneumonia Vaccination Status for Older Adults

85.02

72.92

ACO-16

Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow Up

62.38

70.69

ACO-17

Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

91.38

90.48

ACO-18

Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan

28.02

61.98

ACO-19

Colorectal Cancer Screening

70.98

64.58

ACO-20

Breast Cancer Screening

79.41

70.05

ACO-21

Preventive Care and Screening: Screening for High Blood Pressure and Follow-up Documented

N/A

76.84

ACO-42

Statin Therapy for the Prevention and Treatment of Cardiovascular Disease

73.02

79.89

ACO-27

Diabetes Mellitus: Hemoglobin A1c Poor Control

N/A

18.24

ACO-41

Diabetes: Eye Exam  

N/A

44.94

ACO-28

Hypertension (HTN): Controlling High Blood Pressure

N/A

70.52

ACO-30

Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic

N/A

85.05

ACO-31

Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)

N/A

88.67

ACO-33

Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy – for patients with CAD and Diabetes or Left Ventricular Systolic Dysfunction (LVEF<40%)

N/A

79.67

Please note, the ACO-40 Depression Remission at 12 months quality measure is not included in public reporting due to low samples.

Other Related Info